Last reviewed · How we verify
NCT03652090: Epiithelix
Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis
trial testing cell sampling in Cystic Fibrosis in 112 participants. Completed in 3 March 2016.
3 March 2016
Quick facts
| Lead sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 112 |
| Start date | 1 September 2010 |
| Primary completion | 3 March 2016 |
| Estimated completion | 3 March 2016 |
Drugs / interventions tested
- cell sampling
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France — full company profile →
Who can join
Eligibility, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
characterization of CFTR function and expression in nasal primary cells collected from patients with cystic fibrosis in comparison to their parents, healthy heterozygotes and healthy controls
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M, Krishan A, Patel S, Sinha IP, et al · · 2019 · cited 18× · PMID 30616300 · DOI 10.1002/14651858.cd009841.pub3
Verify or expand the search:
- PubMed search for NCT03652090
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other Institut National de la Santé Et de la Recherche Médicale, France trials
Trials by the same sponsor.
- NCT07311213 — GENES AND AUTISM - IPSC · NA · not yet recruiting
- NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting
- NCT06906042 — Multimodal Cardiovascular and Hepatic Population Imaging · recruiting
- NCT06951035 — Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke · NA · not yet recruiting
- NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03652090 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut National de la Santé Et de la Recherche Médicale, France
- Last refreshed: 12 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652090.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing